Murilo Freitas – Página 543

La Agencia Nacional de Regulación, Control y Vigilancia Sanitaria (Arcsa) da a conocer a la población ecuatoriana la alerta publicada por la Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT) de Argentina, la cual informa a la población que se ha detectado la existencia de especialidades medicinales:

COPAXONE 40 mg/ml , principio activo Glatiramer Acetato . Lote C42234. Exp. 04/2018.

TASIGNA, principio activo Nilotinib Clorhidrato 200 mg, 112 cápsulas. Lote SF432. Exp 06/2019.

AVASTIN, principio activo Bevacizumab 400 mg/ml, por 1 vial para uso I.V. después de disolución. Lote H179810. Exp. 02/2018.

KIVEXA por 30 comprimidos recubiertos, vía oral. Lote KC7W. Exp. 10/2019.

La advertencia surge como consecuencia de haberse realizado una serie de allanamientos en distintas ciudades de Argentina, durante los cuales se retiraron unidades de las partidas detalladas en carácter de muestra. Luego de realizarse las verificaciones pertinentes ante los respectivos titulares de registro, pudo constatarse que las mismas son ilegítimas.

Más informaciones por el enlace http://www.controlsanitario.gob.ec/alerta-sobre-lotes-ilegitimos-de-medicamentos-copaxone-tasigna-avastin-y-kivexa/

rss-es

Colombia: Alerta Invima No. 010-2018 – «Vita-Gest». Producto con registro sanitario falso

Murilo Freitas - 13:53, 20 de febrero de 20181,299

Bogotá, 15 de febrero 2018

Nombre del producto: Vita-Gest

Registro sanitario: RSAD16I47707 registro sanitario falso

Presentación comercial: Frasco por 700 gramos

Fabricante(s) / Importador(es): Laboratorio Salud Natural

Fuente de la alerta: Denuncia

Fuente: https://www.invima.gov.co/alimentos-y-bebidas-aler-sani/alerta-sanitaria-numero-010-2018-vita-gest-pdf/download.html

Inicio Mensajes

El Presidente Tabaré Vázquez de Uruguay es copresidente de la Comisión Independiente Mundial de Alto Nivel de la OMS sobre enfermedades no transmisibles

Murilo Freitas - 13:33, 20 de febrero de 2018790

[Texto original en inlgés]

16 February 2018 | Geneva – WHO is announcing today a new high-level commission, comprised of heads of state and ministers, leaders in health and development and entrepreneurs. The group will propose bold and innovative solutions to accelerate prevention and control of the leading killers on the planet – noncommunicable diseases (NCDs) like heart and lung disease, cancers, and diabetes.

The WHO Independent Global High-level Commission on NCDs is co-chaired by President Tabaré Vázquez of Uruguay; President Maithripala Sirisena of Sri Lanka; President Sauli Niinistö of Finland; Veronika Skvortsova, Minister of Healthcare of the Russian Federation; and Sania Nishtar, former Federal Minister of Pakistan.

(…)

The new Commission was established by WHO Director-General Dr Tedros Adhanom Ghebreyesus and runs until October 2019. It will provide actionable recommendations to contribute to the Third United Nations General Assembly High-level Meeting on NCDs scheduled for the second half of 2018. This will include the submission of its first report to Dr Tedros in early June.

(

For more information go to http://www.who.int/mediacentre/news/releases/2018/world-leaders-ncds/en/

rss-es

TECENTRIQ (atezolizumab) – Risk of Myocarditis

Murilo Freitas - 13:25, 20 de febrero de 2018775

Audiences

Healthcare professionals including oncologists, uro-oncologists, urologists, oncology nurses, oncology pharmacists, emergency room staff, and other healthcare professionals providing care to cancer patients, including those working in hospitals, cancer centers, oncology clinics, and pharmacies.

Key messages

Severe cases of myocarditis have been reported in patients being treated with TECENTRIQ (atezolizumab) in clinical trials.
Healthcare professionals are advised to:
- monitor patients receiving TECENTRIQ for signs and symptoms of myocarditis.
- withhold TECENTRIQ therapy in patients with Grade 2 myocarditis.
- permanently discontinue TECENTRIQ treatment in patients with Grade 3 or 4 myocarditis.
- administer corticosteroids and/or additional immunosuppressive agents as clinically indicated to TECENTRIQ treated patients who develop myocarditis.
The Canadian Product Monograph has been updated to include this new safety information.

For more information go to http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2018/65990a-eng.php

Posting date: February 14, 2018